ABILITYPHARMA

Ability Pharmaceuticals is a clinical stage drug discovery and development biopharmaceutical company

PIPELINE

ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France

SCIENCE

AbilityPharma investigates cancer drugs inducing autophagy by binding receptors PPARα and PPARγ

PHASE 2 CLINICAL TRIAL ONGOING AS FIRST-LINE THERAPY IN PATIENT WITH EITHER ADVANCED/METASTATIC ENDOMETRIAL CANCER OR LUNG CANCER. PATIENTS BEING RECRUITED AT VALL D'HEBRON INSTITUT D'ONCOLOGIA VHIO (BARCELONA), INSTITUT GUSTAVE ROUSSY IGR (PARIS), INSTITUT CATALÀ D'ONCOLOGIA ICO (L’HOSPITALET, BADALONA AND GIRONA), CENTRE LÉON BÉRARD (LYON), INCLIVA (VALENCIA), INSTITUT PAOLI-CALMETTES (MARSEILLE) AND HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO (SEVILLE).

AbilityPharma is a biopharmaceutical company focused on creating the future of oncology by developing innovative therapies that address unmet medical needs. The company was established in 2009 with one product, ABTL0812, an oral autophagy-inducer targeted therapy in phase 2 clinical trials in patients with endometrial cancer and in squamous NSCLC.

Media Center

12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
22.11.2019

In the media

Ability Pharma receives the acknowledgement from Cerdanyola Empresarial + info
13.09.2019

In the media

Ability reinforces the direction and rises 2 million euros from Inveready and Everis + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG